MedTrace Logo

Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML

NCT03922100 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2026-03-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to explore safety, tolerability, including the maximum tolerated dose and the recommended Phase II dose (RP2D), and antitumor activity of NMS-03592088 in adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML).

Conditions

  • Acute Myeloid Leukemia (AML)
  • Chronic Myelomonocytic Leukemia (CMML)

Interventions

DRUG

NMS-03592088

Route of administration: Oral

Sponsors & Collaborators

  • Nerviano Medical Sciences

    lead INDUSTRY

Principal Investigators

  • Alessandro Rambaldi, MD · ASST Papa Giovanni XXIII

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-03
Primary Completion
2024-08-29
Completion
2024-08-29
FDA Drug
Yes

Countries

  • France
  • Italy
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03922100 on ClinicalTrials.gov